The promising data from our own preclinical in vivo data and the BEACON CRC trial led us to the hypothesis that vertical inhibition of EGFR and its downstream effector MEK could be a valid approach to improve the management of patients with RAS mutated CRC. Here, EGFR is linked to colorectal carcinoma.